QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC
QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC
Recruiting · NCT06786026 · Registry updated 2025-02-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 2 | 2025-02-06 | NCT06786026 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Fudan University | 653 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Fudan University Shanghai Cancer Center | Shanghai | China | 257 |